Skip to content

ARTEMIS Synovial Markers in Arthritis Childhood

ARTEMIS Synovial Markers in Arthritis Childhood

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02505828
Acronym
ARTEMIS
Enrollment
30
Registered
2015-07-22
Start date
2015-04-30
Completion date
2018-04-30
Last updated
2020-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis, Septic Arthritis

Keywords

Arthritis, septic, Juvenile idiopathic arthritis, diagnosis, proteomic, cytokine, monocytes

Brief summary

The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.

Interventions

PROCEDUREArticular punction, salivary samples, blood sample

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Septic arthritis with bacteriological identification * Juvenile idiopathic arthritis beyond the ILAR definition * Having acute arthritis requiring an articular draining * Child benefiting from a national insurance scheme * Collection of the consent of the parents or the legal representative

Exclusion criteria

* Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)\> 1,5 * Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining. * Treatment by antibiotic begun more than 24 hours before the draining.

Design outcomes

Primary

MeasureTime frameDescription
Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis.1 dayIdentify blood sampling biomarkers of Arthritis childhood

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026